Furthermore, high expression levels of CXCL9 and CCL5 were associated with an increased number of tumor-infiltrating CD8+ T cells and better outcomes after PD-1 inhibition in not only patients with ovarian cancer, but also those with other cancers, including colon, lung, and breast cancer23. Here, CCL5 is linked to neoplasm.